New Delhi [India], March 31 (ANI): Meeting of Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) will be held on Wednesday to deliberate on emergency use authorisation application of Russian vaccine Sputnik V.
New Delhi [India], February 24 (ANI): The Central Drugs Standard Control Organisation's (CDSCO) Subject Expert Committee (SEC) has recommended additional immunogenicity data from Dr Reddy's Laboratories which applied to the national drugs regulator seeking emergency use approval for Sputnik
New Delhi [India], February 24 (ANI): The Central Drugs Standard Control Organisation's (CDSCO) Subject Expert Committee (SEC) is going to meet on Wednesday afternoon to discuss Dr Reddy's Laboratories application seeking emergency use approval (EUA) for SputnikV, a Russian Vaccine.
New Delhi [India], December 29 (ANI): Importers and manufacturers required to take licence from the Central Licensing Authority or State Licensing Authority for the import and manufacture of nebulizers, BP monitoring devices, digital thermometers, and glucometer with effect from January 1, s
New Delhi [India], December 9 (ANI): The Ministry of Health and Family Welfare on Wednesday dismissed the media report about the rejection of Serum Institute India (SII) and Bharat Biotech's emergency use authorisation of COVID vaccine and called it "fake".
Moscow [Russia], October 23 (ANI): The Russian Sputnik V vaccine against COVID-19 will be tested in India on 100 volunteers, the Indian Central Drugs Standard Control Organisation's Drug Controller General (DCGI) told Sputnik on Thursday.
New Delhi [India], October 22 (ANI): The expert panel at Central Drugs Standard Control Organisation (CDSCO) has recommended the top drugs regulator to grant permission to Bharat Biotech to conduct phase III clinical trial using indigenous covid19 vaccine--Covaxin, with subject to the condit
New Delhi [India], October 10 (ANI): The expert panel at Central Drugs Standard Control Organisation (CDSCO) has asked drug maker Bharat Biotech to submit safety and immunogenicity data from ongoing phase II trial in order to conduct phase III clinical trial of indigenous COVID-19 vaccine, C
New Delhi [India], September 18 (ANI): The Central Drugs Standard Control Organisation (CDSCO) said the requirements and guidelines to conduct clinical trial or grant of permission for the marketing of new drugs including vaccines are prescribed under New Drugs and Clinical Trials Rules, 201
New Delhi [India], Aug 19 (ANI): The Subject Expert Committee (SEC) at the Central Drugs Standard Control Organisation (CDSCO) has recommended that the country's top drug regulator grant permission for phase 3 clinical trial using Thymosin @-1 injection 1.6 mg on moderate to severe COVID-19
New Delhi [India], July 31 (ANI): The Subject Expert Committee at Central Drugs Standard Control Organisation (CDSCO) has recommended to the top drug regulator to grant permission to Serum Institute of India (SII) to conduct phase two and three clinical trials in India on a potential COVID-1
New Delhi [India], July 29 (ANI): The Central Drugs Standard Control Organisation (CDSCO) has advised the Serum Institute of India (SII) to submit a revised protocol to perform the clinical trials in India for potential COVID-19 vaccine.